The United Kingdom's publicly financed National Health Service has granted near-veto power over drug reimbursement decisions to the National Institute for Health and Clinical Excellence, an independent organization known as NICE. As a result, British health authorities are expected to adopt or deny new medical technology based on NICE's assessment of the benefits of this technology versus its impact on health-care costs. This process and the resulting delay in coverage have generated intense controversy in the UK. At the same time, NICE's operation has aroused interest in constructing a similar mechanism in the United States. At this conference, Andrea Sutcliffe, deputy chief executive of NICE, a group of British and American analysts, and an American biomedical industry representative will examine NICE’s method and its implications for U.S. policy.
What's new on AEI
|Holder will regret his refusal to obey the Constitution|
|'Flood Wall Street' climate protesters take aim at their corporate allies|
|3 opportunities for better US-India defense ties|
|Is Nicolás Maduro Latin America's new man at the United Nations?|
We welcome you to join us as Brown shares her perspective on the role of the courts in seeking educational justice and advocating for continued reform.
AEI welcomes you to this Philanthropic Freedom Project event, in which Novogratz will describe her work investing in early-stage enterprises, what she has learned at the helm of Acumen, and the role entrepreneurship can play in the fight against global poverty.